SINGLE-CENTER, PROSPECTIVE STUDY ON THE EFFICACY AND SAFETY OF MICRO-FOCUSED ULTRASOUND WITH VISUALIZATION FOR THE NON-INVASIVE TREATMENT OF MODERATE TO SEVERE FACIAL ACNE

被引：0
|
作者：
Munavalli, Gilly [1 ]
机构：
[1] Dermatol Laser & Vein Specialists Carolinas, Charlotte, NC USA
来源：
LASERS IN SURGERY AND MEDICINE | 2013年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
51
引用
收藏
页码：18 / 19
页数：2
相关论文
共 50 条
  • [31] Real-world effectiveness and safety of Janus kinase 1 inhibitors for the treatment of moderate-to-severe atopic dermatitis: a single-center, prospective study in China
    Chen, Yihui
    Cao, Qiaozhi
    Peng, Cong
    Zhou, Bingjing
    Jiang, Yu
    Chen, Xiang
    Li, Jie
    FRONTIERS OF MEDICINE, 2024, 18 (04) : 752 - 756
  • [32] Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study
    Li, Gaojie
    Gu, Yuanxia
    Zou, Qin
    Wang, Yiyi
    Xiao, Yue
    Xia, Dengmei
    Zhan, Tongying
    Zhou, Xingli
    Wang, Qian
    Yan, Wei
    Li, Wei
    DERMATOLOGY AND THERAPY, 2022, 12 (09) : 2105 - 2115
  • [33] A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
    Daniela Mikhaylov
    Ana Pavel
    Christopher Yao
    Grace Kimmel
    John Nia
    Peter Hashim
    Anjali S. Vekaria
    Mark Taliercio
    Giselle Singer
    Rachel Karalekas
    Danielle Baum
    Yasaman Mansouri
    Mark G. Lebwohl
    Emma Guttman-Yassky
    Archives of Dermatological Research, 2019, 311 : 29 - 36
  • [34] A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
    Mikhaylov, Daniela
    Pavel, Ana
    Yao, Christopher
    Kimmel, Grace
    Nia, John
    Hashim, Peter
    Vekaria, Anjali S.
    Taliercio, Mark
    Singer, Giselle
    Karalekas, Rachel
    Baum, Danielle
    Mansouri, Yasaman
    Lebwohl, Mark G.
    Guttman-Yassky, Emma
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2019, 311 (01) : 29 - 36
  • [35] Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study
    Gaojie Li
    Yuanxia Gu
    Qin Zou
    Yiyi Wang
    Yue Xiao
    Dengmei Xia
    Tongying Zhan
    Xingli Zhou
    Qian Wang
    Wei Yan
    Wei Li
    Dermatology and Therapy, 2022, 12 : 2105 - 2115
  • [36] Efficacy and Safety of Dapagliflozin in the Treatment of Adult Primary IgA Nephropathy: A Single-Center, Prospective, Open, Randomized Controlled Study
    Fei Xiao
    Ling Wang
    Zi Dai Huan
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [37] Prospective real-life single-center study on the efficacy and safety of ofatumumab for the treatment of highly active multiple sclerosis
    Moiola, Lucia
    Gattuso, Irene
    Guerrieri, Simone
    Genchi, Angela
    Nozzolillo, Agostino
    Zanetta, Chiara
    Ferre, Laura
    Martire, Sofia
    Esposito, Federica
    Zaccone, Tiziana
    Rocca, Maria Assunta
    Filippi, Massimo
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 622 - 622
  • [38] Osteoid Osteoma: Magnetic Resonance guided High Intensity Focused Ultrasound for entirely non-invasive treatment. A Prospective developmental study
    Napoli, A.
    de Soccio, V
    Cartocci, G.
    Boni, F.
    Anzidei, M.
    Catalano, C.
    PROCEEDINGS FROM THE 14TH INTERNATIONAL SYMPOSIUM ON THERAPEUTIC ULTRASOUND, 2017, 1821
  • [39] A single-center, open-label study on the use of injectable poly-L-lactic acid for the treatment of moderate to severe scarring from acne or varicella
    Beer, Kenneth
    DERMATOLOGIC SURGERY, 2007, 33 (02) : S159 - S167
  • [40] Impact of ultrasound-guided high-intensity focused ultrasound for the treatment of uterine fibroids on ovarian reserve and quality of life: a single-center prospective cohort study
    Gu, Wei
    Yuan, Jiangjing
    Zhou, Yun
    Li, Yuhong
    Wang, Yudong
    BMC WOMENS HEALTH, 2024, 24 (01)
12345